CA3032686A1 — Use of ganaxolone for treating status epilepticus in a subject

USPTO Abstract

In one aspect there is described use of a pharmaceutical composition comprising ganaxolone or a pharmaceutically acceptable salt thereof, and a carrier, for treating status epilepticus in a subject diagnosed with status epilepticus wherein the pharmaceutical composition or a pharmaceutically acceptable salt thereof is for administration intravenously. In another aspect there is described use of an effective amount of ganaxolone for treating status epilepticus in a subject diagnosed with status epilepticus, wherein the effective amount of ganaxolone is for administration as an intravenous infusion to provide a ganaxolone plasma concentration of less than about 900 ng hr/ml.